Feasibility of serial neurocognitive assessment using Cogstate during and after therapy for childhood leukemia

Authors: Peter D Cole, Soo Young Kim, Yuelin Li, Adrian Schembri, Kara M Kelly, Maria-Luisa Sulis, Lynda Vrooman, Jennifer J G Welch, Sameera Ramjan, Lewis B Silverman, Stephen A Sands

Journal: Supportive Care in Cancer

Year Published: 2023

Purpose Neurocognitive impairment is frequently observed among survivors of childhood acute lymphoblastic leukemia (ALL) within the domains of attention, working memory, processing speed, executive functioning, and learning and memory. However, few studies have characterized the trajectory […]

Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia

Authors: Stephen A Sands, Brian T Harel, Mirko Savone, Kara Kelly, Veena Vijayanathan, Jennifer Greene Welch, Lynda Vrooman, Lewis B Silverman, Peter D Cole

Journal: Supportive Care in Cancer

Year Published: 2016

Purpose: Neurocognitive impairment is frequently observed among acute lymphoblastic leukemia (ALL) survivors within the domains of intelligence, attention, processing speed, working memory, learning, and memory. However, few have investigated treatment-induced changes in neurocognitive function during the […]

Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer’s Disease

Authors: Annie M Racine, Lindsay R Clark, Sara E Berman, Rebecca L Koscik, Kimberly D Mueller, Derek Norton, Christopher R Nicholas, Kaj Blennow, Henrik Zetterberg, Bruno Jedynak, Murat Bilgel, Cynthia M Carlsson, Bradley T Christian, Sanjay Asthana, Sterling C Johnson

Journal: Journal of Alzheimer's Disease

Year Published: 2016

It is not known whether computerized cognitive assessments, like the CogState battery, are sensitive to preclinical cognitive changes or pathology in people at risk for Alzheimer’s disease(AD). In 469 late middle-aged participants from the Wisconsin Registry […]

A 24-week Study to Evaluate the Effect of Rilapladib on Cognition and Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease

Authors: Gareth Maher-Edwards, Jeni De'Ath, Carly Barnett, Arseniy Lavrov, Andrew Lockhart

Journal: Alzheimer's & Dementia

Year Published: 2015

Background: The lipoprotein-associated phospholipase A2 inhibitor (Lp-PLA2), rilapladib (SB659032), is being evaluated as a potential treatment to slow the progression of Alzheimer’s disease (AD). Methods: One hundred twenty-four subjects with possible mild AD and with neuroimaging […]

Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder

Authors: Taisuke Yoshida, Masatomo Ishikawa, Tomihisa Niitsu, Michiko Nakazato, Hiroyuki Watanabe, Tetsuya Shiraishi, Akihiro Shiina, Tasuku Hashimoto, Nobuhisa Kanahara, Tadashi Hasegawa, Masayo Enohara, Atsushi Kimura, Masaomi Iyo, Kenji Hashimoto

Journal: Public Library of Science One

Year Published: 2012

Background: Meta-analyses have identified serum levels of brain-derived neurotrophic factor (BDNF) as a potential biomarker for major depressive disorder (MDD). However, at the time, commercially available human ELISA kits are unable to distinguish between proBDNF (precursor […]

Back to Publications